Small Cell Lung Carcinoma
"Small Cell Lung Carcinoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).
| Descriptor ID |
D055752
|
| MeSH Number(s) |
C04.588.894.797.520.109.220.624 C08.381.540.140.750 C08.785.520.100.220.750
|
| Concept/Terms |
Small Cell Lung Carcinoma- Small Cell Lung Carcinoma
- Small Cell Lung Cancer
- Oat Cell Lung Cancer
- Small Cell Cancer Of The Lung
- Carcinoma, Small Cell Lung
- Oat Cell Carcinoma of Lung
|
Below are MeSH descriptors whose meaning is more general than "Small Cell Lung Carcinoma".
Below are MeSH descriptors whose meaning is more specific than "Small Cell Lung Carcinoma".
This graph shows the total number of publications written about "Small Cell Lung Carcinoma" by people in this website by year, and whether "Small Cell Lung Carcinoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Small Cell Lung Carcinoma" by people in Profiles.
-
Improved False-Positive Rates and the Overestimation of Unintended Harm from Lung Cancer Screening. Lung. 2019 06; 197(3):327-332.
-
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 02 01; 37(4):278-285.
-
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). J Thorac Oncol. 2018 09; 13(9):1393-1399.
-
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Lung Cancer. 2017 02; 104:126-130.
-
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 Jun 01; 18(11):3163-9.
-
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011 Mar 01; 29(7):909-16.
-
Intracranial metastatic disease spares the limbic circuit: a review of 697 metastatic lesions in 107 patients. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):504-12.